Syneron Candela Announces Updates In Patent Infringement Cases
|
WAYLAND, Mass., Nov. 7, 2018 /PRNewswire/ -- Syneron Medical Ltd. and its subsidiary Candela Corporation (collectively, Syneron Candela), a leading global aesthetic device company announced updates today to several patent infringement lawsuits. In April 2018, defending its Profound RF based Microneedle product, Syneron Candela filed patent infringement complaints against 18 manufacturers and distributors of fractional RF micro-needle dermatological treatment systems in both the U.S. International Trade Commission in Washington, D.C. and in federal district court. The accused infringing products include Secret RF by ilooda Co., Ltd. and Cutera, Inc.; Fraxis Duo by ilooda Co., Ltd., Emvera Technologies, LLC and Rohrer Aesthetics, LLC; Fractora by Invasix Ltd., Invasix, Inc. and InMode MD Ltd.; Legend Pro by Lumenis Ltd and Pollogen Ltd; 3DEEP by EndyMed Medical Ltd. and EndyMed Medical Inc.; INTRAcel by Jeisys Medical, Inc. and Perigee Medical LLC; Infini by Lutronic, Corp. and Lutronic, Inc.; and Vivace by Sung Hwan E&B Co. Ltd, Aesthetics Biomedical, Inc. and Cartessa Aesthetics LLC. The lawsuit filed with the ITC seeks to block importation into the U.S. of all fractional RF micro-needle products and is currently scheduled for trial on May 6, 2019.
Unrelated to the above mentioned fractional RF micro-needling case, a patent infringement lawsuit concerning Sublative technology and involving different patents initiated in January 2016 by Syneron Candela's former owners against InMode Ltd and Invasix in the US District Court for the Central District of California recently resulted in the asserted claims of those unrelated patents being held invalid over prior art. On the same day that judgment was entered, the company filed an appeal with the Court of Appeals for the Federal Circuit. Syneron Candela intends to vigorously pursue its pending appeal concerning its Sublative patents. "Dr. Dieter Manstein, at Massachusetts General Hospital, is the inventor on the two patents being asserted in the fractional RF micro-needle litigation filed with the International Trade Commission. Those two patents protecting our Profound RF based Microneedle product were not involved in the Sublative litigation," says Geoffrey Crouse, CEO of Syneron Candela. "In addition to our heavy investment in developing groundbreaking technologies, the core of our market approach centers around building clinical trust with our customers and using our technology to change lives. Through our twelve recently launched National Centers of Excellence across North America and Canada dedicated to sharing clinical excellence, we continue to develop and expand the knowledge and patient access to our market-leading technologies, such as the Vbeam Prima, Gentle Pro Series, Profound and Picoway. We take our commitment to protecting our technology and the trust of our physician partners seriously and will continue to strongly defend our patents," concludes Mr. Crouse. Candela® Media Contact:
SOURCE Candela |
View original content to download multimedia: